Publications by authors named "Pilichou K"

The benefits of cardiac rehabilitation (CR) have been demonstrated in patients after myocardial infarction (MI), and in patients with chronic heart failure (HF). The core components of the CR program include improvement in exercise tolerance and optimization of coronary risk factors (i.e.

View Article and Find Full Text PDF

The newly proposed classification of cardiomyopathies, referred to as 'the Padua Classification', is based on both pathobiological basis (genetics, molecular biology, and pathology) and clinical features (morpho-functional and structural ventricular remodelling as evidenced by cardiac magnetic resonance). Cardiomyopathies are grouped into tree main categories and characterized by a designation combining both 'anatomical' and 'functional' features: hypertrophic/restrictive, dilated/hypokinetic, and scarring/arrhythmogenic; each cardiomyopathy group includes either genetic or non-genetic aetiologic variants. This novel approach aims to enhance the diagnostic accuracy and to support 'disease-specific' therapeutic strategies, with the objective to improve patient management and outcome.

View Article and Find Full Text PDF

Almost 40 years after the description of arrhythmogenic cardiomyopathy (ACM), arrhythmic risk stratification remains central to patient management. Antiarrhythmic therapy may involve the use of antiarrhythmic drugs as well as invasive tools such as catheter ablation, with the implantation of an implantable cardioverter defibrillator being of utmost importance. Given the wide phenotypic variability of ACM, the first step in arrhythmic risk stratification requires a thorough assessment of clinical, morphological, and electrical parameters.

View Article and Find Full Text PDF

Importance: Filamin C truncating variants (FLNCtv) are a rare cause of cardiomyopathy with heterogeneous phenotypic presentations. Despite a high incidence of life-threatening ventricular arrhythmias and sudden cardiac death (SCD), reliable risk predictors to stratify carriers of FLNCtv are lacking.

Objective: To determine factors predictive of SCD/major ventricular arrhythmias (MVA) in carriers of FLNCtv.

View Article and Find Full Text PDF
Article Synopsis
  • Arrhythmogenic cardiomyopathy (ACM) is a heart disease characterized by scarring that affects the heart's electrical stability, making diagnosis complicated due to the lack of a single definitive test.
  • Initially defined in 1994 and revised in 2010, diagnostic criteria for ACM primarily focused on the right ventricle, but the introduction of the Padua Criteria in 2020 expanded these criteria to include left ventricular variants and emphasized advanced imaging for diagnosis.
  • The latest updates, known as the European Task Force criteria, were published in late 2023, further refining the understanding of ACM and highlighting the significance of non-ischemic myocardial scarring and arrhythmogenic risk across different phenotypes.
View Article and Find Full Text PDF
Article Synopsis
  • * Diagnostic criteria for CMA have transformed since 1994, with significant revisions in 2010 and a critical update in 2020 that introduced pathways for diagnosing left ventricular variants, emphasizing cardiac magnetic resonance imaging.
  • * The most recent revisions in 2023 by the European Task Force included an important new concept: "scarring/arrhythmogenic cardiomyopathy," acknowledging the diversity of symptoms and paths of the disease regardless of its cause.
View Article and Find Full Text PDF
Article Synopsis
  • Arrhythmogenic Cardiomyopathy (ACM) is a heart condition that causes problems with how the heart beats and can lead to heart weakness due to scarring in the heart muscle.
  • Diagnosing ACM is tricky because there isn't just one test to do it; instead, doctors need to use a combination of different rules and tests.
  • Over the years, experts have updated the way they diagnose ACM, starting from the first criteria in 1994 to new guidelines in 2023 that help better understand the condition and its effects on the heart.
View Article and Find Full Text PDF

Over the last 20 years, the scientific progresses in molecular biology and genetics in combination with the increasing use in the clinical setting of contrast-enhanced cardiac magnetic resonance (CMR) for morpho-functional imaging and structural myocardial tissue characterization have provided important new insights into our understanding of the distinctive aspects of cardiomyopathy, regarding both the genetic and biologic background and the clinical phenotypic features. This has led to the need of an appropriate revision and upgrading of current nosographic framework and pathobiological categorization of heart muscle disorders. This article proposes a new definition and classification of cardiomyopathies that rely on the combination of the distinctive pathobiological basis (genetics, molecular biology and pathology) and the clinical phenotypic pattern (morpho-functional and structural features), leading to the proposal of three different disease categories, each of either genetic or non-genetic etiology and characterized by a combined designation based on both "anatomic" and "functional" features, i.

View Article and Find Full Text PDF

Arrhythmogenic cardiomyopathy (AC) is a hereditary cardiac disorder characterized by the gradual replacement of cardiomyocytes with fibrous and adipose tissue, leading to ventricular wall thinning, chamber dilation, arrhythmias, and sudden cardiac death. Despite advances in treatment, disease management remains challenging. Animal models, particularly mice and zebrafish, have become invaluable tools for understanding AC's pathophysiology and testing potential therapies.

View Article and Find Full Text PDF

Dilated cardiomyopathy (DCM) is a common cause of heart failure (HF) and heart transplantation (HTx), with genetic factors playing a significant role. In recent years, the RNA-binding protein motif 20 (), which affects the gene splicing of various proteins with different cellular functions, was identified as the first DCM gene with regulatory properties. Variants of have been associated with severe forms of DCM.

View Article and Find Full Text PDF
Article Synopsis
  • Arrhythmogenic cardiomyopathy (ACM) is a genetic heart condition that can lead to sudden death, and understanding its genetic factors is crucial for their diagnosis.
  • A study of 320 ACM patients in Italy identified 35 rare genetic variants, mainly in non-desmosomal genes, with significant findings in the filamin C (FLNC) gene specifically, which accounted for over two-thirds of pathogenic variants.
  • The results suggest that while these non-desmosomal variants are present in some ARVC patients, they are more prevalent in ALVC patients, indicating that clinical decisions should prioritize genes with strong supporting evidence.
View Article and Find Full Text PDF

Background: Desmin (DES) pathogenic variants cause a small proportion of arrhythmogenic cardiomyopathy (ACM). Outcomes data on DES-related ACM are scarce.

Objectives: This study sought to provide information on the clinical phenotype and outcomes of patients with ACM caused by pathogenic variants of the DES gene in a multicenter cohort.

View Article and Find Full Text PDF

Background: Defects of mitophagy, the selective form of autophagy for mitochondria, are commonly observed in several cardiovascular diseases and represent the main cause of mitochondrial dysfunction. For this reason, mitophagy has emerged as a novel and potential therapeutic target.

Methods: In this review, we discuss current evidence about the biological significance of mitophagy in relevant preclinical models of cardiac and vascular diseases, such as heart failure, ischemia/reperfusion injury, metabolic cardiomyopathy and atherosclerosis.

View Article and Find Full Text PDF

Background: In recent years, it has become evident that arrhythmogenic cardiomyopathy (ACM) displays a wide spectrum of ventricular involvement. Furthermore, the influence of various clinical phenotypes on the prognosis of the disease is currently being assessed.

Objectives: The purpose of this study was to evaluate the impact of phenotypic expression in ACM on patient outcomes.

View Article and Find Full Text PDF

Introduction: Sudden cardiac death (SCD) is a serious threat. In individuals under the age of 35 years sudden arrhythmic death is the most frequent cause. In younger persons, genetically determined cardiac diseases (eg, cardiomyopathies and ion-channel diseases) account for an important proportion of these cases.

View Article and Find Full Text PDF

Arrhythmogenic cardiomyopathy (AC) is an inherited disorder characterized by progressive loss of the ventricular myocardium causing life-threatening ventricular arrhythmias, syncope and sudden cardiac death in young and athletes. About 40% of AC cases carry one or more mutations in genes encoding for desmosomal proteins, including Desmoplakin (Dsp). We present here the first stable Dsp knock-out (KO) zebrafish line able to model cardiac alterations and cell signalling dysregulation, characteristic of the AC disease, on which environmental factors and candidate drugs can be tested.

View Article and Find Full Text PDF

The history of arrhythmogenic cardiomyopathy (AC) as a genetically determined desmosomal disease started since the original discovery by Lancisi in a four-generation family, published in 1728. Contemporary history at the University of Padua started with Dalla Volta, who haemodynamically investigated patients with "auricularization" of the right ventricle, and with Nava, who confirmed familiarity. The contemporary knowledge advances consisted of (a) AC as a heart muscle disease with peculiar electrical instability of the right ventricle; (b) the finding of pathological substrates, in keeping with a myocardial dystrophy; (c) the inclusion of AC in the cardiomyopathies classification; (d) AC as the main cause of sudden death in athletes; (e) the discovery of the culprit genes coding proteins of the intercalated disc (desmosome); (f) progression in clinical diagnosis with specific ECG abnormalities, angiocardiography, endomyocardial biopsy, 2D echocardiography, electron anatomic mapping and cardiac magnetic resonance; (g) the discovery of left ventricular AC; (h) prevention of SCD with the invention and application of the lifesaving implantable cardioverter defibrillator and external defibrillator scattered in public places and playgrounds as well as the ineligibility for competitive sport activity for AC patients; (i) genetic screening of the proband family to unmask asymptomatic carriers.

View Article and Find Full Text PDF

Background: Chest pain is experienced by patients with cardiac amyloidosis (CA), but a systematic investigation of its frequency, underlying etiologies and clinical significance is lacking.

Methods: Clinical, echocardiographic, laboratory characteristics, available coronary arteries imaging and endomyocardial biopsy (EMB) findings of 174 patients with CA (n = 104 with transthyretin, ATTR; n = 70 with light chains, AL) were analyzed.

Results: Chest pain was reported in 66 (38%) CA patients.

View Article and Find Full Text PDF

The presence of multiple pathogenic variants in desmosomal genes (DSC2, DSG2, DSP, JUP, and PKP2) in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) has been linked to a severe phenotype. However, the pathogenicity of variants is reclassified frequently, which may result in a changed clinical risk prediction. Here, we present the collection, reclassification, and clinical outcome correlation for the largest series of ARVC patients carrying multiple desmosomal pathogenic variants to date (n = 331).

View Article and Find Full Text PDF

Hypertrophic cardiomyopathy (HCM) is an inherited myocardial disease at risk of sudden cardiac death and heart failure, even requiring heart transplantation. A "muscular mitral-aortic discontinuity" has been reported during surgery in the obstructive form. We aimed to validate these findings through pathological analysis of HCM heart specimens from the cardiovascular pathology tissue registry.

View Article and Find Full Text PDF
Article Synopsis
  • Arrhythmogenic cardiomyopathy (S/ACM) is a heart muscle disease affecting both the right and left ventricles, characterized by loss of heart muscle tissue replaced by scar tissue, which increases the risk of dangerous heart rhythms and impacts heart function.
  • The term S/ACM includes various genetic or acquired conditions that show similar scarring features, and the updated "Padua criteria" help improve diagnosis by incorporating advanced imaging techniques.
  • Treatment focuses on managing arrhythmias and heart failure, with implantable cardioverter defibrillators (ICDs) being the only proven life-saving option, though choosing the right patients for this therapy poses significant challenges.
View Article and Find Full Text PDF
Article Synopsis
  • A new variant of arrhythmogenic cardiomyopathy, called arrhythmogenic left ventricular cardiomyopathy (ALVC), has been studied, focusing on its effects during pregnancy, as there is limited information on this topic.
  • A study analyzed the health of 35 female ALVC patients, observing that 46% had pregnancies with no major health issues related to heart function reported during or after pregnancy.
  • The results showed that both childbearing and nulliparous women had similar heart health outcomes, suggesting pregnancy in ALVC patients can be managed without significant complications.
View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionb95pt08efna2tvlpeipd31vojo5fgr06): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once